Navigation Links
MetaMorphix, Inc. Announces Sale
Date:2/4/2011

CALVERTON, Md., Feb. 4, 2011 /PRNewswire/ -- MetaMorphix, Inc., an animal biotechnology company, announced its intention to sell all, or substantially all, of its assets as part of its reorganization under a sale in Chapter 11 pursuant to section 363 of the Bankruptcy Code. The Company also announced that American MedTech Advisors has been retained to assist in the sale of the Company.

The Company will be accepting bids for any or all of its assets until 4:00 p.m., March 3, 2011. Qualified bidders will be invited to participate in an auction, which will be held on March 8, 2011 at 9:00 a.m. at the law offices of Pinckney, Harris & Weidinger, LLC, 1220 N. Market St., Wilmington, DE. Final court approval is expected on March 9, 2011.

MetaMorphix, Inc. has two technology platforms -- animal genomics, and growth and differentiation factors. The animal genomics business is operated as a wholly owned subsidiary, MMI Genomics, which is located in Davis, CA. MMI Genomics is a leading provider of DNA testing for the livestock and companion animal markets. For the livestock industry, MMI Genomics offers parentage and disease testing for cattle breeders and breed registries. It also has developed predictive markers for several of the most important production and meat quality traits in beef cattle. MMI Genomics has also licensed its trait prediction technology to livestock breeders -- Hubbard in chicken, and Newsham in swine. For the companion animal industry, MMI Genomics offers parentage testing for canine breed registries. As well, the Company was the first to introduce a DNA test that can determine the breed composition in mixed-breed dogs.

MetaMorphix's growth and differentiation platform was licensed from The Johns Hopkins University and is operated from the corporate headquarters in Calverton, MD. The Company's lead growth factor is Myostatin, which is a natural regulator of skeletal muscle. Potential indications for Myostatin in human health include treatment of muscular diseases such as muscle wasting, age-related loss of muscle, and muscular dystrophy. Myostatin has also been shown to have potential for the treatment of metabolic diseases such as Type II diabetes and obesity. In agriculture, Myostatin has the potential to dramatically improve livestock production efficiency and meat quality.For more information on the Company, please contact:Dan D'AgostinoAmerican MedTech Advisors212-209-3885 ddagostino@ameritechadvisors.comorLinda Yaswen, Ph.D.VP Strategic PlanningMetaMorphix, Inc.301-575-2512lyc@metamorphixinc.comFor information on the bidding procedures, please contact:Adam Hiller, Esq. or Kevin Capuzzi, Esq.Pinckney, Harris & Weidinger, LLC302-504-1497 ahiller@phw-law.comkcapuzzi@phw-law.com
'/>"/>

SOURCE MetaMorphix
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):